BIXT BIOXYTRAN, INC
Pharmaceutical Preparations · OTC · SEC CIK 1445815 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-57.2%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-1,453.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,582.1%
Debt / equity—
Current ratio0.03x
Interest coverage-25.47x
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-1,092.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $454,000 | $112,337 | $1.15M | $1.28M | $2.01M |
| SG&A expense | $648,229 | $1.17M | $1.40M | $834,679 | $1.61M |
| Operating income | -$1.84M | -$2.22M | -$3.80M | -$2.44M | -$4.21M |
| Interest expense | $134,314 | $84,240 | $193,191 | — | $2.02M |
| Pretax income | -$2.12M | -$2.38M | -$4.56M | -$2.67M | -$4.53M |
| Net income | -$2.12M | -$2.37M | -$4.47M | -$2.47M | -$4.03M |
| EPS (basic) | -0.02 | -0.02 | -0.03 | -0.02 | -0.04 |
| EPS (diluted) | -0.02 | -0.02 | -0.03 | -0.02 | -0.04 |
| Weighted avg. shares (diluted) | 91.84M | 138.60M | 133.97M | 112.71M | 106.25M |
| Banking | |||||
| Deposits | $111,547 | — | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $509,914 | $5,154 | $26,086 | $295,401 | $72,358 |
| Current assets | $513,465 | $5,154 | $26,086 | $295,401 | $72,358 |
| Intangibles | $145,087 | $133,540 | $113,296 | $75,535 | $46,932 |
| Total assets | $658,552 | $138,694 | $139,382 | $370,936 | $119,290 |
| Current liabilities | $3.25M | $1.93M | $3.24M | $3.67M | $3.28M |
| Short-term debt | — | $48,000 | — | — | — |
| Total liabilities | $3.25M | $1.93M | $3.24M | $3.67M | $3.28M |
| Shareholders' equity | -$2.59M | -$1.79M | -$2.42M | -$2.71M | -$3.16M |
| Shares outstanding | 108.15M | 86.78M | 144.64M | 123.35M | 110.84M |
| Cash flow statement | |||||
| Operating cash flow | -$526,455 | -$381,316 | -$775,375 | -$1.80M | -$1.70M |
| Investing cash flow | -$23,091 | -$28,194 | -$44,301 | -$32,247 | -$36,931 |
| Financing cash flow | $1.05M | $388,578 | $550,361 | $2.06M | $1.76M |
| Stock-based compensation | $197,376 | $634,025 | $177,421 | $139,982 | $582,862 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.